Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially spar...
Quest Diagnostics launched an ultrasensitive blood-based MRD test to monitor multiple myeloma treatment, potentially reducing invasive bone marrow aspirations and associated costs.
Why it mattersQuest Diagnostics' ultrasensitive blood MRD test for multiple myeloma lets oncologists replace bone marrow aspirations, cutting costs.